AMPB

AcronymDefinition
AMPBAmphotericin B
AMPBAssociation of Micro-Power Broadcasters (Berkeley, CA)
AMPBAdvanced Materials and Processing Branch (US NASA)
AMPBAliansi Mahasiswa Peduli Bangsa (Indonesian: Concern for the Nation Student Alliance)
AMPBAmerican Pacific Bank B (stock symbol)
References in periodicals archive ?
Adjunct therapy of recombinant cytokines (IL-17A and IFN-[gamma]) along with sub-optimal dose of AmpB, influence significant improvement in body weight but not change in organ weight
Adjunct therapy of recombinant cytokines (IL-17A and IFN-[gamma]) along with sub-optimal dose of AmpB, inhibit the parasitic growth in visceral organs of Leishmaniadonovani infected mice:
Change in pro-inflammatory cytokines gene expression in infected mice upon adjunct therapy of recombinant cytokines (IL-17A and IFN-[gamma]) along with sub-optimal dose of AmpB
Change in anti-inflammatory gene expression in infected mice upon adjunct therapy of recombinant cytokines (IL-17A and IFN-[gamma]) along with sub-optimal dose of AmpB
When we evaluated the sub-optimal dose of AmpB with cytokine(s) primed group of mice, we observed more than 95% of parasitic clearance.
The Oral AmpB technology is also moving into in vitro testing with study partners in Montreal, and will examine the role of this formulation in targeting latent HIV reservoirs, which remain in individuals despite enormous therapeutic advances in the treatment of HIV/AIDS.
The modified version is called the AMP-Bilateral (AMPB).
Abbreviations: 6MWT = 6-minute walk test, AIS = Abbreviated Injury Scale, AMP = Amputee Mobility Predictor, AMPB = AMP-Bilateral, ANOVA = analysis of variance, BLLA = bilateral lower-limb amputation, BTFA = bilateral transfemoral amputation, BTTA = bilateral transtibial amputation, IRB = Institutional Review Board, NISS = New Injury Severity Score, SF-36 = 36-Item Short Form Health Survey, SM = servicemember, TTA/TFA = combination transtibial/transfemoral amputation, WRAMC = Walter Reed Army Medical Center.
The annual use of echinocandins increased significantly during 2001-2013 (Spearman r = 0.98; p < 0.0001) (Figure 2), whereas annual azole and ampB use did not (data not shown).
Fungemia was detected in samples from 37 of 68 patients (54%) while they were being treated with antifungal agents, specifically with echinocandins (n = 21, 57%), ampB (n = 9, 24%), azoles (n = 6, 16%), or antifungal combinations (n = 1, 3%) (Table 2).
kefyr (82%); the incidence density for the species increased substantially over time (Figure 1) and was positively associated with the annual use of echinocandins (p = 0.004), but not azoles or ampB. Dufresne et al.
The susceptibility of 4 cryopreserved isolates ([S.sub.1], [S.sub.3], [S.sub.4], and [S.sub.6]; Table) to AmpB and to miltefosine was studied in the in vitro promastigote and axenic amastigote form by determining the concentrations inhibiting parasite growth by 50% (1,2).